PDT’s PHOTONIC TUMOR THERAPY is used since 2004 in humans in leading Austrian Tumor Centers in well-selected indications on named-patient base. Since then excellent clinical data of the side effect free therapy have led physicians to expand the use into multiple other indications. After being granted CE Mark for its third generation ultimate high power catheter-based, therapy laser PDT is engaged in the commercialization of its reimbursed technology with the support of its CE marked field-specialist service.
PDT plans to internationalize the commercialization of PHOTONIC TUMOR THERAPY to further IP protected territories in collaboration with strategic partners, licensees and/or franchisees, investors.
To ensure the most efficient use of its technology throughout all territories and medical disciplines and to offer its partners a highly efficient hands-on training and support facility, PDT is establishing a KNOW HOW TRANSFER CENTER near Vienna, Austria.
The overall market size for tumor treatment modalities continues to grow due to an aging population, circumstances of life and better diagnostics.
Only for the currently targeted indications, i.e. cancer of the bile duct, bladder, gastric cardia, cervix, colon, esophagus (Barrett's), lung, pancreas, and rectum, approximately 1,6M new cases in the EC and approximately 1M in the US are estimated per year with a future CAGR of 3.5%. Due to its excellent data and proven efficacy, PDT’s technology has the potential to capture up to 20% of these indications within 4 years after start of commercialization in partnerships.
PDT’s proprietary platform technology has impressively proven the therapeutic impact in various indications and holds the promise to be as effective in other upcoming oncology indications and beyond where abnormal cell growth requires eradication.